Investors

Marinus is committed to maximizing shareholder value by developing and commercializing ganaxolone for treatment of drug-resistant seizures and neuropsychiatric disorders for both hospital and home settings.

 






 
NASDAQ: MRNS
*Delayed quote courtesy of Google Finance.

 

  Presentations View our latest presentations View All

Sasha Damouni Ellis

VP, Investor Relations & Corporate Communications
Marinus Pharmaceuticals, Inc.

Email
484-253-6792 (o)
484-801-4669 (f)

Contact Us